1. Home
  2. KOSS vs ATOS Comparison

KOSS vs ATOS Comparison

Compare KOSS & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Koss Corporation

KOSS

Koss Corporation

HOLD

Current Price

$4.13

Market Cap

39.3M

ML Signal

HOLD

Logo Atossa Therapeutics Inc.

ATOS

Atossa Therapeutics Inc.

HOLD

Current Price

$4.38

Market Cap

36.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KOSS
ATOS
Founded
1953
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Consumer Electronics/Appliances
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
39.3M
36.2M
IPO Year
1994
2010

Fundamental Metrics

Financial Performance
Metric
KOSS
ATOS
Price
$4.13
$4.38
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$31.67
AVG Volume (30 Days)
28.8K
395.4K
Earning Date
04-29-2026
04-20-2026
Dividend Yield
N/A
N/A
EPS Growth
10.00
16.67
EPS
N/A
N/A
Revenue
$12,624,170.00
$1,758.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
2.93
N/A
52 Week Low
$4.00
$0.53
52 Week High
$8.59
$7.56

Technical Indicators

Market Signals
Indicator
KOSS
ATOS
Relative Strength Index (RSI) 41.99 63.90
Support Level N/A $0.69
Resistance Level $5.04 $7.56
Average True Range (ATR) 0.17 0.38
MACD -0.03 -0.13
Stochastic Oscillator 18.75 39.51

Price Performance

Historical Comparison
KOSS
ATOS

About KOSS Koss Corporation

Koss Corp is engaged in the design, manufacture, and sale of stereo headphones and related accessory products. It operates in the audio/video industry segment of the home entertainment industry. The company markets a line of headphones, wireless Bluetooth headphones, wireless Bluetooth speakers, computer headsets, telecommunications headsets, and active noise-canceling headphones. The majority of the firm's revenue is derived from sales of stereo headphones. The Company also sells products to distributors for resale to school systems, and directly to other manufacturers for inclusion with their own products.

About ATOS Atossa Therapeutics Inc.

Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

Share on Social Networks: